BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9325244)

  • 21. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
    Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
    J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
    Arion D; Kaushik N; McCormick S; Borkow G; Parniak MA
    Biochemistry; 1998 Nov; 37(45):15908-17. PubMed ID: 9843396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase.
    Burke DH; Scates L; Andrews K; Gold L
    J Mol Biol; 1996 Dec; 264(4):650-66. PubMed ID: 8980676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
    Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
    Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
    J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and Moloney murine leukemia virus reverse transcriptase.
    Gao HQ; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 1999 Dec; 294(5):1097-113. PubMed ID: 10600369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.
    Coutsinos D; Invernizzi CF; Xu H; Brenner BG; Wainberg MA
    Antivir Chem Chemother; 2010 Jan; 20(3):117-31. PubMed ID: 20054099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
    Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
    Schneider A; Corona A; Spöring I; Jordan M; Buchholz B; Maccioni E; Di Santo R; Bodem J; Tramontano E; Wöhrl BM
    Nucleic Acids Res; 2016 Mar; 44(5):2310-22. PubMed ID: 26850643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
    Shafer RW; Eisen JA; Merigan TC; Katzenstein DA
    J Virol; 1997 Jul; 71(7):5441-8. PubMed ID: 9188616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
    Currens MJ; Mariner JM; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thermostable HIV-1 group O reverse transcriptase variants with the same fidelity as murine leukaemia virus reverse transcriptase.
    Barrioluengo V; Alvarez M; Barbieri D; Menéndez-Arias L
    Biochem J; 2011 Jun; 436(3):599-607. PubMed ID: 21446917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.
    Quiñones-Mateu ME; Albright JL; Mas A; Soriano V; Arts EJ
    J Virol; 1998 Nov; 72(11):9002-15. PubMed ID: 9765445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.